Astera Labs, Inc. ALAB
364.62
4.11
1.14%
as of 25 Sep
- Market cap
- $63.7B
- P/E
- 168×
Follow ALAB
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
222.59 | 68.93 | 126.99 | 164.54 |
+8 more quarters Free account |
P/S ratio |
69.27 | 18.68 | 32.47 | 45.34 | |
P/FCF ratio |
300.94 | 54.58 | 98.25 | 142.89 | |
P/Operating CF |
949.63 | 250.83 | 290.60 | 419.39 | |
P/B ratio |
48.25 | 12.52 | 20.30 | 25.78 | |
Price to Tangible BV |
50.95 | 13.31 | 20.59 | 25.78 | |
EV/Sales |
68.23 | 17.50 | 31.08 | 43.77 | |
EV/EBITDA |
293.13 | 77.28 | 153.75 | 310.95 | |
EV/Operating CF |
244.28 | 45.71 | 82.98 | 120.00 | |
EV/FCF |
296.41 | 51.13 | 94.03 | 137.94 | |
Quick Ratio |
8.80 | 10.55 | 9.56 | 11.66 | |
Current Ratio |
10.05 | 11.30 | 10.24 | 12.78 | |
Net Debt/EBITDA |
(13.59) | (18.41) | (17.44) | (20.59) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.75 | 0.72 | 0.66 | 0.61 | |
Operating CF/Net income |
0.57 | 0.93 | 2.12 | 0.86 | |
Capex/Depreciation |
(6.94) | (3.02) | (15.68) | 38.06 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
34.63% | 40.74% | 34.66% | 34.23% | |
Selling, General and Administrative Expense of Revenue |
15.91% | 15.46% | 16.16% | 17.99% | |
Intangible Assets out of Total Assets |
0.05 | 0.05 | 0.01 | 0.00 | |
Share Based Compensation of Revenue |
16.31% | 15.86% | 15.29% | 17.67% | |
Graham Net Nets |
0.02 | 0.07 | 0.04 | 0.04 | |
Graham Number |
22.11 | 17.69 | 15.54 | 14.26 | |
Earnings Yield |
0.45% | 1.45% | 0.79% | 0.61% | |
Free Cash Flow Yield |
0.33% | 1.83% | 1.02% | 0.70% | |
Revenue per Share |
2.28 | 1.81 | 1.63 | 1.38 | |
Operating CF per Share |
0.51 | 0.44 | 0.57 | 0.47 | |
Capex per Share |
(0.12) | (0.04) | (0.11) | (0.07) | |
Free Cash Flow per Share |
0.39 | 0.39 | 0.46 | 0.39 | |
Cash per Share |
7.27 | 6.94 | 7.14 | 6.78 | |
Shareholders Equity per Share |
10.01 | 8.75 | 8.19 | 7.60 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
10.01 | 8.75 | 8.19 | 7.60 | |
Free Cash Flow |
67.21 | 67.01 | 76.58 | 65.88 | |
Working Capital |
1,487.59 | 1,287.89 | 1,228.99 | 1,189.20 | |
Capital Expenditures |
(20.47) | (7.59) | (18.69) | (12.29) | |
Net Current Asset Value |
1,446.10 | 1,247.67 | 1,193.84 | 1,160.71 | |
EV/EBIT |
299.91 | 78.26 | 152.78 | 296.87 | |
Capex to Sales |
0.05 | 0.02 | 0.07 | 0.05 | |
Net Profit Margin |
39.01% | 26.04% | 16.62% | 39.52% | |
Price to Operating Income |
304.49 | 83.54 | 159.63 | 307.52 | |
| Other line items | |||||
Average Receivables |
108.39 | 102.29 | 61.01 | 34.14 | |
Average Payables |
42.75 | 42.67 | 34.64 | 22.18 | |
Average Inventory |
86.19 | 55.61 | 51.10 | 38.04 | |
Average Assets |
1,601.45 | 1,390.45 | 1,293.17 | 1,192.12 | |
Average Common Equity |
1,430.71 | 1,267.76 | 1,164.22 | 1,080.67 |
Columns are period end dates